Last reviewed · How we verify
TEMIRI
At a glance
| Generic name | TEMIRI |
|---|---|
| Also known as | Temozolomide + Irinotecan, Intensified Induction TEMIRI |
| Sponsor | Italian Sarcoma Group |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- First-line Treatment of Ewing Tumours With Primary Extrapulmonary Dissemination in Patients From 2 to 50 Years (CombinaiR3) (PHASE2)
- The Sagittarius Trial (PHASE3)
- High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) (PHASE3)
- Study of Sequential High-dose Chemotherapy in Children With High Risk Medulloblastoma (PHASE1, PHASE2)
- Protocol for the Treatment of Metastatic Ewing Sarcoma (PHASE2)
- Temozolomide and Irinotecan in Patients With MGMT Silenced Colorectal Cancer After Adjuvant Chemotherapy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TEMIRI CI brief — competitive landscape report
- TEMIRI updates RSS · CI watch RSS
- Italian Sarcoma Group portfolio CI